Latest Breaking News On - தீபக் சதா - Page 1 : comparemela.com

Published: Apr 27, 2021 - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021 BOULDER, Colo., April 27, 2021 (GLOBE NEWSWIRE) Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced completion of patient enrollment in the Phase 3 pivotal Cardigan I study and that the Cardigan II study has surpassed 50% enrollment. Both studies are evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis. “We are encouraged with the progress we are making with our Phase 3 pivotal clinical studies, and we remain on track to report topline results from both studies in the fourth quarter of 2021,” said Deepak Chadha, Chief Research and Development Officer of Brickell. “We continue to experience s

United statesNicholas bodorDeepak chadhaResearch professorBrickell biotech incCompany nasdaqInternational hyperhidrosis societyBodor laboratories incUniversity of floridaExchange commissionChief researchDevelopment officerHyperhidrosis disease severity measure axillaryNew drug applicationBodor laboratoriesGraduate research professor emeritus